Blog

Jul 16, 2024, 14:12

Elisabetta Bonzano: Comparative biological activity of palbociclib and ribociclib in HR+ breast cancer

Elisabetta Bonzano, Associate Professor at MIUR, shared on X:

“Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.

Both CDK4/6 inhibitors effectively modulate key biological pathways in HR+/HER2‑ breast cancer, nuances in their impact, particularly on the HER2‑enriched signature, are dose‑dependent, influenced by the addition of fulvestrant and warrant further investigation.”

Elisabetta Bonzano

Visit the article website.
Source: Elisabetta Bonzano/X

7th Multidisciplinary Breast Cancer Conference Associate Professor qualification Breast Cancer cancer CDK4/6 Elisabetta Bonzano HR-/HER2+ MIUR OncoDaily Oncology

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage